Effects of Highly Absorbable Curcumin in Patients with Impaired Glucose Tolerance and Non-Insulin-Dependent Diabetes Mellitus

Table 4

Percentage changes of parameter in placebo and Theracurmin® groups.

		Placebo		Theracurmin®	value
ΔBMI	17		15		0.077
ΔSBP	17		14		0.944
ΔDBP	17	-3.1 [-10.7, 19.8]	14	0.0 [-14.7, 9.8]	0.662
ΔHbA1c	17		15		0.388
ΔBS	17	-0.7 [-13.4, 40.8]	14	-5.4 [-17.6, 2.4]	0.219
ΔTG	17	-3.7 [-32.6, 13.4]	15	-8.5 [-25.4, 24.0]	0.835
ΔLDL-C	17	-3.5 [-13.5, 2.4]	15	1.3 [-8.2, 18.5]	0.220
ΔHDL-C	17		15		0.675
ΔUA	17		15		0.688
Δγ-GTP	17		15		0.531
ΔCre	17		15		0.072
ΔSAA-LDL	14		14		0.891
ΔAT-LDL	14		14		0.233
Δadiponectin	14		13		0.160
Δleptin	14		13		0.872
Δhs-CRP	14	-1.7 [-27.5, 108.0]	13	-1.2 [-40.3, 42.5]	0.771
ΔCCr	17	2.5 [-4.1, 6.3]	15	-2.6 [-7.5, 2.1]	0.168

BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HbA1c: hemoglobin A1c; BS: blood sugar; TG: triglyceride; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; UA: uric acid; γ-GTP: γ-glutamyl transpeptidase; Cre: creatinine; SAA-LDL: serum amyloid A-LDL; AT-LDL: a1-antitrypsin-LDL; hs-CRP: high-sensitivity C-reactive protein; CCr: creatinine clearance.